The role of blood glucose-lowering drugs in the light of the UKPDS

Diabetes, Obesity and Metabolism

Volumn 1, Issue SUPPL. 2, 1999, Pages 14-23

  Monnier, L ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002619277     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.1999.0010s2014.x     Document Type: Review

References (49)

1. Andersson DK, Svardsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care, 1995: 18: 1534-1543.
2. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 1995: 18: 258-268.
3. Klein R, Klein BE. Relation of glycemic control to diabetic complications and health outcomes. Diabetes Care, 1998: 21 (Suppl. 3): C39-C43.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998: 352: 837-853.
5. Colwell JA. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Annals of Internal Medicine, 1996: 124: 131-135.
6. Hennessey JV, Bustamante MA, Teter ML, Markert RJ, McDonald SD. Bedtime dosing of glyburide and the treatment of type II diabetes mellitus. American Journal of Medical Science, 1994: 308: 234-238.
7. Bretzel RG, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes, 1998: 106: 369-372.
8. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia, 1996: 39: 1577-1583.
9. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabetic Medicine, 1998: 15: 188-193.
10. Lebovitz HE. Postprandial hyperglycaemic state: importance and consequences. Diabetes Research and Clinical Practice, 1998: 40 (Suppl.): S27-S28.
11. Baron AD. Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Diabetes Research and Clinical Practice, 1998: 40 (Suppl.): S51-S55.
12. Haller H. The clinical importance of postprandial glucose. Diabetes Research and Clinical Practice, 1998: 40 (Suppl.): S43-S49: S43-S49.
13. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care, 1998: 21: 360-367.
14. de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. New England Journal of Medicine, 1995: 333: 1237-1241.
15. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care, 1997: 20: 1822-1826.
16. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs, 1999: 57: 19-29.
17. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care, 1999: 22: S32-S41.
18. Edelman SV. Type II diabetes mellitus. Advances in Internal Medicine, 1998: 43: 449-500.
19. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs, 1998: 55: 225-236.
20. Consensus Statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care, 1995: 18: 1510-1518.
21. Alberti KG, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabetic Medicine, 1988: 5: 275-281.
22. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1999: 22 (Suppl. 1): S5-S19.
23. American Diabetes Association. Tests of glycaemia in diabetes. Diabetes Care, 1999: 22 (Suppl. 1): S77-S79.
24. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care, 1994: 17: 1542-1544.
25. Watkins P. Guidelines for good practice in the diagnosis and treatment of non-insulin dependent diabetes mellitus. Report of a joint working party of the British Diabetic Association, and the research unit of the Royal College of Physicians and the Royal College of General Practitioners. Journal of the Royal College of Physicians of London, 1993: 27: 253-266.
26. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. Journal of the American Medical Association, 1997: 278: 1663-1669.
27. Yki-Jarvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia, 1995: 38: 1378-1388.
28. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care, 1990: 13: 610-630.
29. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes, 1996: 45: 1044-1050.
30. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. New England Journal of Medicine, 1988: 318: 1231-1239.
31. Goke B. Implications of blood glucose, insulin resistance and beta-cell function in impaired glucose tolerance. Diabetes Research and Clinical Practice, 1998: 40 (Suppl.): S15-S20: S15-S20.
32. Monnier L. Non-insulin-dependent diabetes. Epidemiology, etiology, physiopathology, diagnosis, complications, prognosis, treatment. Revue du Practicien, 1995: 45: 1941-1949.
33. Monnier L, Colette C, Avignon A, Percheron C, Lapinski H, Boniface H. Changes in dietary management of diabetic patients. Diabetes and Metabolism, 1998: 24 (Suppl. 3) (24-34): 24-34.
34. Delahanty LM, Halford BN. The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care, 1993: 16: 1453-1458.
35. Kelley D. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Reviews, 1995: 3: 366-377.
36. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs, 1995: 49: 721-749.
37. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care, 1997: 20: 925-928.
38. Trovati M, Burzacca S, Mularoni E, et al. Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycaemic agents: importance of blood glucose monitoring. Diabetologia, 1991: 34: 662-667.
39. Groop LC. Sulfonylureas in NIDDM. Diabetes Care, 1992: 15: 737-754.
40. Melander A. Oral antidiabetic drugs: an overview. Diabetic Medicine, 1996: 13: S143-S147.
41. Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Safety, 1995: 12: 32-45.
42. Pagano G, Marena S, Corgiat-Mansin L, et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabetes and Metabolism, 1995: 21: 162-167.
43. Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care, 1997: 20: 687-691.
44. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 1998: 83: 1515-1522.
45. Rabasa-Lhoret R, Chiasson JL. Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance. Drugs and Aging, 1998: 13: 131-143.
46. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, PiSunyer FX, Krol A. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care, 1994: 17: 20-29.
47. Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care, 1998: 21: 409-415.
48. Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care, 1998: 21: 416-422.
49. Mitrakou A, Tountas N, Raptis AE, Bauer RJ, Schulz H, Raptis SA. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Diabetic Medicine, 1998: 15: 657-660.